<DOC>
	<DOCNO>NCT00414050</DOCNO>
	<brief_summary>This study conduct healthy infant provide new immunogenicity safety data modify process hepatitis B vaccine . This study conduct address following : evaluate immunogenicity safety data 5 microgram dose modify process hepatitis B vaccine compare 10 microgram dose modified process hepatitis B vaccine '' , evaluate another dosing schedule 2 , 4 , 6 month , provide descriptive immunogenicity data another market vaccine ( ENGERIX-Bâ„¢ ) .</brief_summary>
	<brief_title>A Study 2 Doses Hepatitis B Vaccine ( V232 RECOMBIVAX HB ) Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject ( Participant ) healthy infant approximately 2 month age Birth mother know carrier hepatitis B virus another know carrier live close contact subject Subject 's ( Participant ) birth mother receive prenatal care Subject ( Participant ) previous history hepatitis B infection Subject ( Participant ) vaccinate hepatitis B birth mother vaccinate within 6 month birth subject Subject ( Participant ) fever within 72 hour study start Subject ( Participant ) receive bloodderived product birth mother receive bloodderived product within 6 month birth subject</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>2 Months</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>